Trials / Withdrawn
WithdrawnNCT02943603
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
A Phase II Study of Perioperative mFOLFOX6 Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Weijing Sun, MD, FACP · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mFLOFOX6 + pembrolizumab | the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently. |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2019-01-01
- Completion
- 2019-07-01
- First posted
- 2016-10-24
- Last updated
- 2018-07-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02943603. Inclusion in this directory is not an endorsement.